Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Q3 Revenues Increase 9 Percent as Company Turns a Profit

NEW YORK, Oct. 28 (GenomeWeb News) - Molecular Devices yesterday reported a 9-percent increase in revenue and has turned a profit for the third quarter of 2005.


Revenues for the quarter ended Sept. 30 totaled $45.2 million, an 8.8percent increase over last year's revenues of $41.5 million during the same quarter.


"In life sciences, we continued to see strong demand for our SpectraMax M5 bench-top reader," Joseph Keegan, Molecular Devices' president and CEO, said in a statement. "In drug discovery, we saw excellent growth in both our high-throughput electrophysiology and FLIPR product lines."


R&D spendning in the quarter remained flat at $6.4 million, the company said.


Molecular Devices posted a $4.6-million profit in the third quarter, compared with a $1.3-million loss year over year.


As of Sept. 30, Molecular Devices had $12.2 million in cash and cash equivalents.


Molecular Devices said it anticipates revenues of $52 million to $54 million in the fourth quarter, an increase of between 9.4 percent and 13.7 percent. The company also said it anticipates revenues of $181 million to $183 million for the full year of 2005.


For the full year 2006, Molecular Devices said it anticipates revenues of $192 million to $202 million.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.